Citations

Showing 10 of 108094 citations.

Polygenic Scores of Alzheimer’s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden
Przybelski, Scott A. , Lesnick, Timothy G. , Lowe, Val J. , Graff‐Radford, Jonathan , Jack, Clifford R. , Petersen, Ronald C. , Ross, Owen A. , Vemuri, Prashanthi , Initiative, for the Alzheimer’s Disease Neuroimaging, Jack, Clifford R , Vemuri, Prashanthi , Ross, Owen A , Ramanan, Vijay K. , Heckman, Michael G. , Mielke, Michelle M. , Knopman, David S. , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Journal of Alzheimer’s Disease | July 8, 2022 | Volume: 88 | Issue: 4 | Pages: 1615-1625

10.3233/jad-220164 | PMID 35811524 Get It

Background: Brain accumulation of amyloid-β is a hallmark event in Alzheimer’s disease (AD) whose underlying mechanisms are incompletely understood. Case-control genome-wide association studies have implicated numerous genetic variants in risk of clinically diagnosed AD dementia. Objective: To test for associations between case-control AD risk variants and amyloid PET burden in older adults, and to assess whether a polygenic measure encompassing these factors would account for a large proportion of the unexplained variance in amyloid PET levels in the wider population. Methods: We analyzed data from the Mayo Clinic Study of Aging (MCSA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Global cortical amyloid PET burden was the primary outcome. The 38 gene variants from Wightman et al. (2021) were analyzed as predictors, with PRSice-2 used to assess the collective phenotypic variance explained. Results: Known AD risk variants in APOE, PICALM, CR1, and CLU were associated with amyloid PET levels. In aggregate, the AD risk variants were strongly associated with amyloid PET levels in the MCSA ( p = 1.51×10 –50 ) and ADNI ( p = 3.21×10 –64 ). However, in both cohorts the non- APOE variants uniquely contributed only modestly (MCSA = 2.1%, ADNI = 4.4%) to explaining variation in amyloid PET levels. Conclusion: Additional case-control AD risk variants added only modestly to APOE in accounting for individual variation in amyloid PET burden, results which were consistent across independent cohorts with distinct recruitment strategies and subject characteristics. Our findings suggest that advancing precision medicine for dementia may require integration of strategies complementing case-control approaches, including biomarker-specific genetic associations, gene-by-environment interactions, and markers of disease progression and heterogeneity.
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
Aboursheid, Tarek , Albaroudi, Omar , Alahdab, Fares , Aboursheid, Tarek , Alahdab, Fares

Mayo Clinic

Cochrane Database of Systematic Reviews | July 8, 2022 | Volume: 2022 | Issue: 7 | Pages: No page available

10.1002/14651858.cd011808.pub3 | PMID 35802341 Get It

Reconstruction of oral cavity defects using myogenous‐only scapular tip free‐flaps
Barton, Blair M. , Pappa, Andrew K. , Blumberg, Jeffrey M. , Patel, Samip , Patel, Samip N

Mayo Clinic

Laryngoscope Investigative Otolaryngology | July 8, 2022 | Volume: 7 | Issue: 4 | Pages: 955-962

10.1002/lio2.848 | PMID 36000052 Get It

AbstractBackgroundOral cavity reconstruction is very challenging anatomical subsite to reconstruct. Large defects often require free tissue reconstruction to provide the best chance of form and function. Additionally, free tissue reconstruction aids to prevent fistula formation. We aimed to determine outcomes of oral cavity defect reconstruction using scapular tip free flaps with a myogenous intraoral component.MethodsAll patients with a mandibular or maxillary bony defect that included a disruption of the intraoral mucosa component between 07/1/14 and 07/31/17. Patients were reconstructed with a scapular tip free flap, which included a muscular component that was used to recreate the oral mucosa. The primary study outcomes were flap success rates, development of orocutaneous or oronasal fistula, rate of resuming oral diet as well as the occurrence of medical and surgical complications in the first month following surgery. The tested hypothesis was formulated before data collection began.ResultsTwenty‐five patients were identified by the study criteria. There was one (4%) flap that failed, while orocutaneous fistula occurred in two patients (8%). Prior history of osteoradionecrosis was a statistically significant predictor of overall complication (p < .05).ConclusionsIntraoral myogenous reconstruction allows for re‐mucosalization of the oral cavity defect and is associated with high viability and low‐complication rates. In patients with amenable oral mucosal defects, a myogenous scapular tip free flap is a suitable reconstructive option.
The reverse question mark and L.G. Kempe incisions for decompressive craniectomy: A case series and narrative review of the literature
Figueredo, Luisa F , Gamboa-Oñate, Carlos A., Kehayov, Ivo , Rengifo-Hipus, Jorge A., Romero-Castillo, Ingrid J., Rodríguez-Medina, Angie P., Patiño-Gómez, Javier G., Zorro, Óscar , Ordóñez-Rubiano, Edgar G.

Mayo Clinic

Surgical Neurology International | July 8, 2022 | Volume: 13 | Issue: No issue available | Pages: 295

10.25259/sni_59_2022 | PMID 35855131 Get It

Background: Decompressive craniectomy (DC) is a lifesaving procedure, relieving intracranial hypertension. Conventionally, DCs are performed by a reverse question mark (RQM) incision. However, the use of the L. G. Kempe’s (LGK) incision has increased in the last decade. We aim to describe the surgical nuances of the LGK and the standard RQM incisions to treat patients with severe traumatic brain injury (TBI), intracranial hemorrhage (ICH), empyema, and malignant ischemic stroke. Furthermore, to describe, surgical limitations, wound healing, and neurological outcomes related to each technique. Methods: To describe a prospective acquired, case series including patients who underwent a DC using either an RQM or an LGK incision in our institution between 2019 and 2020. Results: A total of 27 patients underwent DC. Of those, ten patients were enrolled. The mean age was 42.1 years (26–71), and 60% were male. Five patients underwent DC using a large RQM incision; three had severe TBI, one ICH, and one ischemic stroke. The other five patients underwent DC using an LGK incision (one ICH, one subdural empyema, and one ischemic stroke). About 50% of patients presented severe headaches associated with vomiting, and six presented altered mental status (drowsy or stuporous). Motor deficits were present in four cases. In patients with ischemic or hemorrhagic stroke, symptoms were directly related to the stroke location. Hospital stays varied between 13 and 22 days. No readmissions were recorded, and no fatal outcome was documented during the follow-up. Conclusion: The utility of the LGK incision is comparable with the classic RQM incision to treat acute brain injuries, where an urgent decompression must be performed. Some of these cases include malignant ischemic strokes, ICH, and empyema. No differences were observed between both techniques in terms of prevention of scalp necrosis and general cosmetic outcomes.
Author response: Cre/lox regulated conditional rescue and inactivation with zebrafish UFlip alleles generated by CRISPR-Cas9 targeted integration
Kambakam, Sekhar , Almeida, Maira P. , Ming, Zhitao, Wierson, Wesley A. , Schultz‐Rogers, Laura , Liu, Fang , Welker, Jordan M. , Ekker, Stephen C. , Clark, Karl J. , Essner, Jeffrey J. , McGrail, Maura

Mayo Clinic

No container title available | July 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.71478.sa2 Get It

Prevalence and clinical characteristics of age-related distance esotropia
Claxton, Matthew R., Bang, Genie M., Martinez‐Thompson, Jennifer M. , Hodge, David O. , Mohney, Brian G., Martinez-Thompson, Jennifer, Claxton, Matthew R.

Mayo Clinic

Strabismus | July 8, 2022 | Volume: 30 | Issue: 3 | Pages: 115-120

10.1080/09273972.2022.2097707 | PMID 35799374 Get It

Design and validation of a FHIR-based EHR-driven phenotyping toolbox
Brandt, Pascal , Pacheco, Jennifer A. , Adekkanattu, Prakash , Sholle, Evan , Stone, Daniel J. , Knaack, David, Xu, Zhenxing , Wang, Fei , Jiang, Guoqian , Pathak, Jyotishman , Brandt, Pascal S , Sholle, Evan T , Knaack, David M, Peng, Yifan , Benda, Natalie C , Luo, Yuan , Rasmussen, Luke V , Pacheco, Jennifer A , Abedian, Sajjad , Xu, Jie , Luo, Yuan , Rasmussen, Luke V.

Mayo Clinic

Journal of the American Medical Informatics Association | July 8, 2022 | Volume: 29 | Issue: 9 | Pages: 1449-1460

10.1093/jamia/ocac063 | PMID 35799370 Get It

Abstract Objectives To develop and validate a standards-based phenotyping tool to author electronic health record (EHR)-based phenotype definitions and demonstrate execution of the definitions against heterogeneous clinical research data platforms. Materials and Methods We developed an open-source, standards-compliant phenotyping tool known as the PhEMA Workbench that enables a phenotype representation using the Fast Healthcare Interoperability Resources (FHIR) and Clinical Quality Language (CQL) standards. We then demonstrated how this tool can be used to conduct EHR-based phenotyping, including phenotype authoring, execution, and validation. We validated the performance of the tool by executing a thrombotic event phenotype definition at 3 sites, Mayo Clinic (MC), Northwestern Medicine (NM), and Weill Cornell Medicine (WCM), and used manual review to determine precision and recall. Results An initial version of the PhEMA Workbench has been released, which supports phenotype authoring, execution, and publishing to a shared phenotype definition repository. The resulting thrombotic event phenotype definition consisted of 11 CQL statements, and 24 value sets containing a total of 834 codes. Technical validation showed satisfactory performance (both NM and MC had 100% precision and recall and WCM had a precision of 95% and a recall of 84%). Conclusions We demonstrate that the PhEMA Workbench can facilitate EHR-driven phenotype definition, execution, and phenotype sharing in heterogeneous clinical research data environments. A phenotype definition that integrates with existing standards-compliant systems, and the use of a formal representation facilitates automation and can decrease potential for human error.
Outcomes of Mayo Clinic reBoot camps for postimplementation training in the electronic health record
Gordon, Joel , Belford, Sylvia M , Aranguren, Dawn, Fleming, Richard, Gajarawala, Nikunj M., Heiderscheit, Jon, Laabs, Susan, Looft, Kathryn A, Rosedahl, Jordan K., Gordon, Joel E , Aranguren, Dawn L, Blair, David, Laabs, Susan B, Blair, David, Fleming, Richard, O’Horo, John C.

Mayo Clinic

Journal of the American Medical Informatics Association | July 8, 2022 | Volume: 29 | Issue: 9 | Pages: 1518-1524

10.1093/jamia/ocac107 | PMID 35799373 Get It

Abstract Objective After a new electronic health record (EHR) was implemented at Mayo Clinic, a training program called reBoot Camp was created to enhance ongoing education in response to needs identified by physician leaders. Materials and Methods A reBoot camp focused on EHR topics pertinent to ambulatory care was offered from April 2018 through June 2020. There were 37 2-day sessions and 43 1-day sessions, with 673 unique participants. To evaluate outcomes of the reBoot camp, we used survey data to study baseline, immediate, and long-term perceptions of program satisfaction and self-assessed skills with the EHR. The study was conducted among practitioners at a large ambulatory practice network based in several states. Data were collected from April 2018 through January 2021. We analyzed automatically collected metadata and scores that evaluated the amount of personalization and proficiency of use. Results Confidence in skills increased by 13.5 points for general EHR use and was significant in 5 subdomains of use (13–18 point improvement). This degree of user confidence was maintained at the 6-month reassessment. The outcomes of configuration and proficiency scores also improved significantly. Discussion Ongoing education regarding EHR tools is necessary to support continued use of technology. This study was novel because of the amount and breadth of data collected, diversity of user participation, and validation that improvements were maintained over time. Conclusions Participating in a reBoot camp significantly improved user confidence in each domain of the EHR and demonstrated use of best-practice tools. Users maintained gains at the 6-month evaluation phase.
Long-term outcomes of peroral endoscopic myotomy for achalasia: a systematic review and meta-analysis
Vespa, Edoardo , Chandrasekar, Viveksandeep Thoguluva , Spadaccini, Marco , Patel, Harsh K. , Maselli, Roberta , Carlani, Elisa , Hassan, Cesare , Repici, Alessandro , Chandrasekar, Viveksandeep T , Spadaccini, Marco , Hassan, Cesare , Pellegatta, Gaia , Galtieri, P.A. , Sharma, Prateek

Mayo Clinic

Endoscopy | July 7, 2022 | Volume: 55 | Issue: 02 | Pages: 167-175

10.1055/a-1894-0147 | PMID 35798336 Get It

Background The long-term outcomes of esophageal peroral endoscopic myotomy (POEM) are still unknown. Methods We searched electronic databases (MEDLINE/PubMed, EMBASE, Scopus) for studies assessing outcomes after POEM for esophageal achalasia with a minimum median follow-up duration of 36 months. Pooled rates of clinical success and postoperative reflux were calculated and compared with the same values at 12/24/36 months when available. Subgroup analyses were performed to explore the interstudy heterogeneity. Results From 1528 initial records, 11 studies (2017–2021) were included. A total of 2342 patients (age 48.1 [SD 6.8] years; 50.1 % males) with a median follow-up of 48 months (interquartile range 45–60) were analyzed. The pooled clinical success rate was 87.3 % (95 %CI 83.6 %–91.0 %; I2 = 73.1 %). The symptomatic reflux pooled rate was 22.0 % (95 %CI 14.4 %–29.5 %; I2 = 92.7 %). Three cases of peptic strictures and one Barrett’s esophagus were reported. The pooled rate of severe adverse events was 1.5 % (95 %CI 0.5 %–2.5 %; I2 = 52.8 %). Conclusions Long-term clinical efficacy of POEM persisted in 87 % of patients with achalasia. Post-POEM symptomatic reflux remained stable over time. The risk for Barrett’s esophagus and peptic strictures appeared minimal.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Pedrini, Steve , Boonkamp, Lynn, Armstrong, Nicola J. , Luo, Jingqin , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Berman, Sarah , Chhatwal, Jasmeer P. , Graff-Radford, Neill, Day, Gregory S. , Farlow, Martin, Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Perrin, Richard J. , Fagan, Anne M. , Morris, John C. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Luo, Jingqin , Berman, Sarah , Boonkamp, Lynn , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John , Karch, Celeste M. , Cruchaga, Carlos , Farlow, Martin R. , Lee, Jae Hong , McDade, Eric , Mori, Hiroshi , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | July 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v2 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.